We believe that the surest path to a better future is through technological advancement and that the new frontier of technology lies at the interface of computation, engineering and biology. Our mission is to improve health with technologies that transform the way that antibody-based therapies are discovered. We aim to become the centralized operating system for next-generation antibody discovery.
Our full-stack, artificial intelligence-, or AI, powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. We believe our technology increases the speed and the probability of success of therapeutic antibody discovery, including enabling discovery against targets that may otherwise be intractable.
In a collaboration with Eli Lilly and Company, or Lilly, we applied our technology stack to co-develop LY-CoV555, a potential antibody therapy to treat and prevent COVID-19. Starting from a single blood sample obtained from a convalescent patient, we and our partners identified a viable antibody drug candidate within three weeks that advanced into clinical testing 90 days after initiation of the program. Lilly progressed into these clinical trials at a greatly accelerated pace as a result of the Coronavirus Treatment Acceleration Program, which is a special emergency program for possible coronavirus therapies created by the U.S. Food and Drug Administration, or FDA, in 2020 to expedite the development of potentially safe and effective life-saving treatments to combat the COVID-19 pandemic.
(Note: The AbCellera Biologics IPO was upsized at pricing: 24.15 million shares were priced at $20 – up from 23.0 million at $17 to $18 in the prospectus.)
|Address||2215 Yukon Street Vancouver, British Columbia, V5Y 0A1, Canada|
|Phone Number||(604) 559-9005|
|View Prospectus:||AbCellera Biologics|
|Revenues||$20.5 mil (last 12 months)|
|Net Income||$0.2 mil (last 12 months)|
|Price range||$20.00 - $20.00|
|Est. $ Volume||$483.0 mil|
|Manager / Joint Managers||Credit Suisse/ Stifel/ Berenberg/ SVB Leerink/ BMO Capital Markets|
|Expected To Trade:||12/11/2020|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|